Zernikow B, Fleischhack G, Hasan C, Bode U
Department of Paediatric, Haematology/Oncology, University Children's Hospital, University of Bonn, Germany.
Mycoses. 1997 Dec;40(9-10):359-61. doi: 10.1111/j.1439-0507.1997.tb00250.x.
Despite its common adverse effects intravenous (i.v.) amphotericin B is an indispensable antifungal drug in childhood oncology. We report here on three cases of painful cyanotic Raynaud's phenomenon after i.v. administration or inhalation of amphotericin B. A liposomal i.v. preparation of amphotericin B was well tolerated by the infants. Spasms of peripheral vessels mediated by thromboxane A2 could be responsible for the Raynaud's phenomenon. Hence, inhibitors of prostaglandin synthesis are suggested for therapy.
